Mitsubishi Tanabe to Focus on Sales Turnaround for Canaglu, Eyes Diabetes and Nephrology Sales of 100 Bil. Yen

August 17, 2016
Takeshi Hirokawa, General Manager of the Product Marketing Department Mitsubishi Tanabe Pharma will work hard this fiscal year to increase the number of medical institutions that prescribe its sodium glucose co-transporter-2 (SGLT-2) inhibitor Canaglu (canagliflozin), which posted sluggish sales last...read more